331 related articles for article (PubMed ID: 11120973)
1. In vitro activity of trovafloxacin against Bacteroides fragilis in mixed culture with either Escherichia coli or a vancomycin- resistant strain of Enterococcus faecium determined by an anaerobic time-kill technique.
Stearne LE; Kooi C; Goessens WH; Bakker-Woudenberg IA; Gyssens IC
Antimicrob Agents Chemother; 2001 Jan; 45(1):243-51. PubMed ID: 11120973
[TBL] [Abstract][Full Text] [Related]
2. In vivo efficacy of trovafloxacin against Bacteroides fragilis in mixed infection with either Escherichia coli or a vancomycin-resistant strain of Enterococcus faecium in an established-abscess murine model.
Stearne LE; Gyssens IC; Goessens WH; Mouton JW; Oyen WJ; van der Meer JW; Verbrugh HA
Antimicrob Agents Chemother; 2001 May; 45(5):1394-401. PubMed ID: 11302801
[TBL] [Abstract][Full Text] [Related]
3. Levofloxacin plus metronidazole administered once daily versus moxifloxacin monotherapy against a mixed infection of Escherichia coli and Bacteroides fragilis in an in vitro pharmacodynamic model.
Hermsen ED; Hovde LB; Sprandel KA; Rodvold KA; Rotschafer JC
Antimicrob Agents Chemother; 2005 Feb; 49(2):685-9. PubMed ID: 15673752
[TBL] [Abstract][Full Text] [Related]
4. Protection of Enterococcus faecalis in mixed cultures with carbapenemase-producing Escherichia coli and Bacteroide fragilis: effect of the bacterial load.
Sevillano D; Aguilar L; Alou L; Giménez MJ; Cafini F; González N; Prieto J
Rev Esp Quimioter; 2013 Sep; 26(3):220-5. PubMed ID: 24080888
[TBL] [Abstract][Full Text] [Related]
5. Activity of trovafloxacin (with or without ampicillin-sulbactam) against enterococci in an in vitro dynamic model of infection.
Zinner SH; Gilbert D; Dudley MN
Antimicrob Agents Chemother; 1998 Jan; 42(1):72-7. PubMed ID: 9449263
[TBL] [Abstract][Full Text] [Related]
6. Effect of recombinant murine granulocyte colony-stimulating factor with or without fluoroquinolone therapy on mixed-infection abscesses in mice.
Stearne LE; Vonk AG; Kullberg BJ; Gyssens IC
Antimicrob Agents Chemother; 2005 Sep; 49(9):3668-75. PubMed ID: 16127038
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of trovafloxacin in an in vitro pharmacodynamic simulation of an intraabdominal infection.
Alou L; Anta ML; Del Potro MG; Fuentes F; Balcabao IP; Gomez-Lus ML; Prieto J
Int J Antimicrob Agents; 1999 Jul; 12(2):135-9. PubMed ID: 10418758
[TBL] [Abstract][Full Text] [Related]
8. In vitro effect of the presence of human albumin or human serum on the bactericidal activity of daptomycin against strains with the main resistance phenotypes in Gram-positives.
Cafini F; Aguilar L; González N; Giménez MJ; Torrico M; Alou L; Sevillano D; Vallejo P; Prieto J
J Antimicrob Chemother; 2007 Jun; 59(6):1185-9. PubMed ID: 17412725
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics and microbiology of trovafloxacin in animal models of surgical infection.
Onderdonk AB
Am J Surg; 1998 Dec; 176(6A Suppl):39S-45S. PubMed ID: 9935256
[TBL] [Abstract][Full Text] [Related]
10. [Activity of trovafloxacin and ten other antimicrobials against gram negative anaerobic bacilli].
Chávez M; García López JL; Coronilla J; Bernal S; Valverde A; Martín Mazuelos E
Rev Esp Quimioter; 1998 Dec; 11(4):349-52. PubMed ID: 9990149
[TBL] [Abstract][Full Text] [Related]
11. Intracellular activity of trovafloxacin (CP-99,219) against Enterococcus faecium.
Herrera-Insúa I; Jacques-Palaz K; Murray BE; Rakita RM
J Antimicrob Chemother; 1997 Apr; 39(4):552-3. PubMed ID: 9145833
[No Abstract] [Full Text] [Related]
12. Exposure-response analysis of tigecycline in pharmacodynamic simulations using different size inocula of target bacteria.
Sevillano D; Aguilar L; Alou L; Giménez MJ; González N; Torrico M; Cafini F; Garcia-Rey C; Garcia-Escribano N; Prieto J
Int J Antimicrob Agents; 2010 Aug; 36(2):137-44. PubMed ID: 20462741
[TBL] [Abstract][Full Text] [Related]
13. Changing patterns of fluoroquinolone resistance among Bacteroides fragilis group organisms over a 6-year period (1997-2002).
Betriu C; Rodríguez-Avial I; Gómez M; Culebras E; Picazo JJ
Diagn Microbiol Infect Dis; 2005 Nov; 53(3):221-3. PubMed ID: 16243476
[TBL] [Abstract][Full Text] [Related]
14. In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis.
Girard AE; Girard D; Gootz TD; Faiella JA; Cimochowski CR
Antimicrob Agents Chemother; 1995 Oct; 39(10):2210-6. PubMed ID: 8619569
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of piperacillin/tazobactam and ertapenem against Bacteroides fragilis and Escherichia coli in pure and mixed cultures.
Valéria Dos Santos K; Diniz CG; Coutinho SC; Apolônio ACM; Geralda de Sousa-Gaia L; Nicoli JR; Farias LM; Roque de Carvalho MA
J Med Microbiol; 2007 Jun; 56(Pt 6):798-802. PubMed ID: 17510265
[TBL] [Abstract][Full Text] [Related]
16. Fluoroquinolone resistance in Bacteroides fragilis following sparfloxacin exposure.
Peterson ML; Hovde LB; Wright DH; Hoang AD; Raddatz JK; Boysen PJ; Rotschafer JC
Antimicrob Agents Chemother; 1999 Sep; 43(9):2251-5. PubMed ID: 10471574
[TBL] [Abstract][Full Text] [Related]
17. The in-vitro activity of trovafloxacin, a new fluoroquinolone, against Gram-positive bacteria.
Sefton AM; Maskell JP; Rafay AM; Whiley A; Williams JD
J Antimicrob Chemother; 1997 Jun; 39 Suppl B():57-62. PubMed ID: 9222071
[TBL] [Abstract][Full Text] [Related]
18. Effect of growth phase and pH on the in vitro activity of a new glycopeptide, oritavancin (LY333328), against Staphylococcus aureus and Enterococcus faecium.
Mercier RC; Stumpo C; Rybak MJ
J Antimicrob Chemother; 2002 Jul; 50(1):19-24. PubMed ID: 12096002
[TBL] [Abstract][Full Text] [Related]
19. Activity of moxifloxacin against Bacteroides fragilis and Escherichia coli in an in vitro pharmacokinetic/pharmacodynamic model employing pure and mixed cultures.
Schaumann R; Goldstein EJ; Forberg J; Rodloff AC
J Med Microbiol; 2005 Aug; 54(Pt 8):749-753. PubMed ID: 16014428
[TBL] [Abstract][Full Text] [Related]
20. In vivo efficacy of trovafloxacin (CP-99,217), a new quinolone, in experimental intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli.
Thadepalli H; Reddy U; Chuah SK; Thadepalli F; Malilay C; Polzer RJ; Hanna N; Esfandiari A; Brown P; Gollapudi S
Antimicrob Agents Chemother; 1997 Mar; 41(3):583-6. PubMed ID: 9055997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
